*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Prof. Ryan Bailey, University of Illinois
Silicon Photonics: A New Paradigm in Multiplexed Bioanalysis
School Colloquia
The concept of personalized medicine is predicated on an ability to comprehend a patient's disease state in a highly informed manner that ideally illuminates an effective, molecularly-targeted treatment strategy. A growing body of evidence suggests that the simultaneous measurement of 10s, 100s, or even 1000s of biomolecular signatures (DNA, RNA, proteins, metabolites, etc.) from a single clinically relevant sample would be incredibly enabling in achieving such an informative diagnosis. Unfortunately, this is an analytical feat that is currently not possible using established methods, thereby limiting the implementation of informative molecular diagnostic and theragnostic strategies in the clinical treatment of disease. In response to this and other bioanalytical challenges that simultaneously require high sensitivity, high level multiplexing capability, and scalable and cost effective sensor fabrication, our group has developed a new biomolecular analysis platform based upon silicon photonic microring resonators. This detection strategy leverages well validated semiconductor fabrication, laser sources from optic telecommunications, and conventional microarraying tools to create highly multiplexed and robust biosensor arrays that are extraordinarily sensitive to biomolecular binding events at the sensor surface. In this talk I will describe our efforts to develop this emerging platform for the analysis of disease-relevant protein and nucleic acid biomarkers in the context of creating multiplexed detection solutions for a range of both clinical diagnostic and fundamental bioanalytical challenges.
For more information contact Prof. Andrew Lyon (404-894-4090).
